Literature DB >> 21476963

Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.

Federica Laudisi1, Manolo Sambucci, Claudio Pioli.   

Abstract

Poly(ADP-ribose) polymerases (PARPs) represent a family of enzymes which synthesize and bind branched polymers of ADP-ribose to acceptor proteins using NAD as a substrate. PARP-1, the prototypical representative of the family, accounts for the majority of the poly(ADP-ribose) polymer synthesis. PARP-1 functions as a DNA nick sensor and signaling molecule binding to ssDNA and dsDNA protecting cells from genomic instability. PARP-1 activity plays a relevant role in the development of inflammatory responses largely contributing to tissue damage in ischemia/reperfusion conditions, such as stroke and myocardial infarction, and in septic shock. Recently, several findings revealed a wider immunological role for PARP-1. It regulates gene transcription in several types of immune cells, including dendritic cells, macrophages and lymphocytes. PARP-1 affects the stimulatory ability of dendritic cells, T cell activation and antibody production. Inhibition of PARP-1 enzymatic activity reduces the secretion of pro-inflammatory cytokines and ameliorates autoimmune diseases in several experimental models. Our recent findings showed that PARP-1 deficiency affects T cell differentiation rendering naïve CD4 T cells prone to differentiate in regulatory T cells. All together these findings show that PARP-1 plays a pivotal role in the balance between pro-inflammatory/effector and anti-inflammatory/regulatory responses, opening new possible therapeutic perspectives.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476963     DOI: 10.2174/187153011797881184

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  16 in total

Review 1.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 2.  Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.

Authors:  Palak Tiwari; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur Grewal
Journal:  Neurochem Res       Date:  2022-04-18       Impact factor: 3.996

Review 3.  Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Authors:  Maria Manuela Rosado; Elisabetta Bennici; Flavia Novelli; Claudio Pioli
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 4.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 5.  ADP-ribosylation in evasion, promotion and exacerbation of immune responses.

Authors:  Maria Manuela Rosado; Claudio Pioli
Journal:  Immunology       Date:  2021-04-12       Impact factor: 7.215

6.  Proteomic dissection of LPS-inducible, PHF8-dependent secretome reveals novel roles of PHF8 in TLR4-induced acute inflammation and T cell proliferation.

Authors:  Özgün Erdoğan; Ling Xie; Li Wang; Bing Wu; Qing Kong; Yisong Wan; Xian Chen
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

7.  PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.

Authors:  Lena N Lupey-Green; Stephanie A Moquin; Kayla A Martin; Shane M McDevitt; Michael Hulse; Lisa B Caruso; Richard T Pomerantz; Jj L Miranda; Italo Tempera
Journal:  Virology       Date:  2017-04-26       Impact factor: 3.616

8.  Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs.

Authors:  Mohamed Tharwat Hegazy; Walaa Ramadan Allam; Mohamed A Hussein; Naguib Zoheir; Luca Quartuccio; Sherif F El-Khamisy; Gaafar Ragab
Journal:  EBioMedicine       Date:  2018-08-20       Impact factor: 8.143

9.  A ribose-functionalized NAD+ with unexpected high activity and selectivity for protein poly-ADP-ribosylation.

Authors:  Xiao-Nan Zhang; Qinqin Cheng; Jingwen Chen; Albert T Lam; Yanran Lu; Zhefu Dai; Hua Pei; Nikolai M Evdokimov; Stan G Louie; Yong Zhang
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

10.  Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Authors:  Gerben R Borst; Ramya Kumareswaran; Hatice Yücel; Seyda Telli; Trevor Do; Trevor McKee; Gaetano Zafarana; Jos Jonkers; Marcel Verheij; Mark J O'Connor; Sven Rottenberg; Robert G Bristow
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.